Cantargia AB (CHIX:CANTAS) Issuance of Debt: kr25.0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:CANTAS Cantargia AB CHIX:CANTAS
33 GF Score
Price kr4.17
! 2 Warning Signs
View Full Analysis

What is Cantargia AB Issuance of Debt?

Cantargia AB CHIX:CANTAS 33 Issuance of Debt is kr25.0 Mil as of Mar. 2026. GuruFocus rates CHIX:CANTAS with a GF Score™ of 33/100. The stock has 2 warning signs investors should review.

Cantargia AB's Issuance of Debt for the three months ended in Mar. 2026 was kr0.0 Mil.

Cantargia AB's Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was kr25.0 Mil.

Cantargia AB Issuance of Debt Related Terms

Cantargia AB Issuance of Debt Historical Data

* Premium members only.

The historical data trend for Cantargia AB's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantargia AB Issuance of Debt Chart

Cantargia AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 25.00

Cantargia AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 25.00 0.00 0.00 0.00
CHIX:CANTAS
33GF Score
Cantargia AB CHIX:CANTAS
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cantargia AB Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr25.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of kr25.0 Mil mean?
Cantargia AB (CHIX:CANTAS) has a Issuance of Debt of kr25.0 Mil as of Mar. 2026. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Cantargia AB and its competitors.
Is Cantargia AB's Issuance of Debt too high?
Cantargia AB's current Issuance of Debt is kr25.0 Mil. Overall, Cantargia AB has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Cantargia AB's Issuance of Debt compare to VRTX and REGN?
Cantargia AB's Issuance of Debt of kr25.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Biotechnology company?
A good Issuance of Debt depends on the Biotechnology industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Cantargia AB and its competitors. Cantargia AB's current Issuance of Debt is kr25.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantargia AB stock overvalued right now?
Cantargia AB (CHIX:CANTAS) has a current Issuance of Debt of kr25.0 Mil. The current Issuance of Debt is kr25.0 Mil. Cantargia AB's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For Cantargia AB (CHIX:CANTAS), the current Issuance of Debt is kr25.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cantargia AB Business Description

Other Exchanges CANTA:Sweden7V3:Germany
Address Scheelevagen 27, Lund, SWE, 223 63
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, which were latter acquired by Otsuka Pharmaceutical in 2025. In addition, the company is also developing a a pre-clinical project CAN14, derived from antibody platform CANxx. Geographically, the company's revenues have been generated in the markets of Japan and United States.
33GF Score

Get the complete analysis for CHIX:CANTAS

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr4.17
Price